CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.44, no.4, pp.438-451, 2019 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 44 Issue: 4
- Publication Date: 2019
- Doi Number: 10.1515/tjb-2019-0038
- Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Page Numbers: pp.438-451
- Keywords: Epithelial ovarian cancer, CA125, HE4, Mesothelin, YKL-40
- Dokuz Eylül University Affiliated: Yes
Abstract
Objective: Cancer Antigen 125 (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) score are used for classification of ovarian masses (benign/malign) in preoperative stage. However, their discrimination capacity are considered insufficient, and greatly effected by histological subtype and menopausal status. This study aimed to investigate diagnostic performance of Human epididymis protein 4 (HE4), Y (tyrosine), K (lysine), and L (leucine)-40 (YKL-40), Mesothelin, Rho GDP dissociation inhibitor beta (LyGDI), CA125 or their combinations in discrimination of benign/malign ovarian diseases in preoperative stage.